ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
Launch of clinical development of avacopan in Hidradenitis Suppurativa (HS), an orphan dermatological disease, remains on track for 2018 –.
Source link
Blog - Latest News
You are here: Home / Uncategorized / ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent ...
Interesting links
Here are some interesting links for you! Enjoy your stay :)Categories
Archive
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
Leave a Reply
Want to join the discussion?Feel free to contribute!